Rie Ono
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rie Ono has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Shin Takayama
Department of Kampo and Integrative Medicine, Tohoku University Graduate School of Medicine
3 shared publications Tadashi Ishii
Department of Kampo and Integrative Medicine Tohoku University Graduate School of Medicine Sendai Miyagi Japan
3 shared publicationsAkiko Kikuchi
Department of Kampo Medicine, Tohoku University Hospital, Sendai, Miyagi, Japan; Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Miyagi, Japan; Department of Kampo and Integrative Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
2 shared publications- Akiko Kikuchi
Department of Kampo and Integrative Medicine Tohoku University Graduate School of Medicine Sendai Miyagi Japan
1 shared publication Chika Akaishi
Department of Kampo Medicine, Tohoku University Hospital, Sendai, Miyagi, Japan
1 shared publication- Hidehisa Saito
Department of Education and Support for Regional Medicine Tohoku University Hospital Sendai Miyagi Japan
1 shared publication
Latest Publications
- Open Access
- 8 September 2026
- Published by Wiley in Traditional & Kampo Medicine
- Vol. 13 (3) , e70085
A Case of Remarkable Improvement in Dizziness and Lightheadedness in an Elderly Patient Treated With Goshajinkigan
- 8 September 2026
- Published by Wiley in Traditional & Kampo Medicine
- Vol. 13 (3) , e70085
Open AccessA Case of Remarkable Improvement in Dizziness and Lightheadedness in an Elderly Patient Treated With Goshajinkigan
- Open Access
- 25 May 2023
- Published by Wiley in Traditional & Kampo Medicine
- Vol. 10 (2) , 150-158
Progress and treatment of “long COVID” in non‐hospitalized patients: A single‐center retrospective cohort study
Background: “Long COVID” or “post‐COVID conditions” describes prolonged symptoms after the acute phase of coronavirus disease 2019 (COVID‐19). However, there is a paucity of published reports on its treatment.Method: This retrospective cohort study included adult, non‐hospitalized patients with COVID‐19 symptoms at least one month after the onset who had been examined at the isolation facility in Miyagi prefecture between October 2020 and September 2021.Results: In total, 70 patients with a median age of 46 (21–69) years were included, and 37 were women (52.9%). The median time from onset to the end of treatment was 46 (28–396) days. Thirty‐eight patients (53.5%) showed improvement in all symptoms, while four (5.7%) did not recover within the study period. The symptoms at six months with high residual rates were dizziness (33.3%), fatigue (14.3%), myalgia (14.3%), abdominal discomfort (14.3%), and taste dysfunction (11.8%). For treatment of prolonged symptoms, formulae of Kampo medicine (Japanese traditional medicine) were used alone or in combination with Western medications in 76%, 66%, 53%, and 66% of patients at 1–2 months, 2–3 months, 3–6 months, and over 6 months respectively. Kampo formulae with anti‐inflammatory effects were used in the early period; however, tonifying formulae and blood stasis‐resolving formulae were used in the late period.Conclusion: Non‐hospitalized patients with COVID‐19 may suffer from persistent symptoms after the acute phase of infection. For the management of long COVID, a comprehensive and holistic approach is needed. Kampo medicine should be considered as a treatment option for long COVID.
- 25 May 2023
- Published by Wiley in Traditional & Kampo Medicine
- Vol. 10 (2) , 150-158
Open AccessProgress and treatment of “long COVID” in non‐hospitalized patients: A single‐center retrospective cohort study
Background: “Long COVID” or “post‐COVID conditions” describes prolonged symptoms after the acute phase of coronavirus disease 2019 (COVID‐19). However, there is a paucity of published reports on its treatment.Method: This retrospective cohort study included adult, non‐hospitalized patients with COVID‐19 symptoms at least one month after the onset who had been examined at the isolation facility in Miyagi prefecture between October 2020 and September 2021.Results: In total, 70 patients with a median age of 46 (21–69) years were included, and 37 were women (52.9%). The median time from onset to the end of treatment was 46 (28–396) days. Thirty‐eight patients (53.5%) showed improvement in all symptoms, while four (5.7%) did not recover within the study period. The symptoms at six months with high residual rates were dizziness (33.3%), fatigue (14.3%), myalgia (14.3%), abdominal discomfort (14.3%), and taste dysfunction (11.8%). For treatment of prolonged symptoms, formulae of Kampo medicine (Japanese traditional medicine) were used alone or in combination with Western medications in 76%, 66%, 53%, and 66% of patients at 1–2 months, 2–3 months, 3–6 months, and over 6 months respectively. Kampo formulae with anti‐inflammatory effects were used in the early period; however, tonifying formulae and blood stasis‐resolving formulae were used in the late period.Conclusion: Non‐hospitalized patients with COVID‐19 may suffer from persistent symptoms after the acute phase of infection. For the management of long COVID, a comprehensive and holistic approach is needed. Kampo medicine should be considered as a treatment option for long COVID.
- Open Access
- 1 January 2001
- Published by Pharmaceutical Society of Japan in Journal of Health Science
- Vol. 47 (6) , 579-582
Prolonged Intake of Isoflavone- and Saponin- Containing Soybean Extract (Nijiru) Supplement Enhances Circulating .GAMMA.-Carboxylated Osteocalcin Concentrations in Healthy Individuals.
- 1 January 2001
- Published by Pharmaceutical Society of Japan in Journal of Health Science
- Vol. 47 (6) , 579-582
Open AccessProlonged Intake of Isoflavone- and Saponin- Containing Soybean Extract (Nijiru) Supplement Enhances Circulating .GAMMA.-Carboxylated Osteocalcin Concentrations in Healthy Individuals.